- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 50
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 36
- States / cities
- Covina, California • El Cajon, California • Long Beach, California + 32 more
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
- Interventions
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
- Drug · Radiation · Device + 1 more
- Lead sponsor
- Alice Bertaina
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
- Interventions
- DB-2304, Placebo, Prednisone
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- La Palma, California • Clearwater, Florida • Orlando, Florida + 3 more
- Conditions
- Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 513 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
- Interventions
- VENT-03, Placebo
- Drug
- Lead sponsor
- Ventus Therapeutics U.S., Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 7 more
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Interventions
- Surovatamig
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Fullerton, California • Allen, Texas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Gusacitinib
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Erythematosus, Graft-versus-host Disease
- Interventions
- Cyclophosphamide, Fludarabine, Tacrolimus, Mycophenolate Mofetil, Rabbit antithymocyte globulin, Total body irradiation, Allogeneic bone marrow transplant
- Drug · Radiation · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Research Triangle Park, North Carolina • Madison, Wisconsin
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Torrance, California • Brandon, Florida • Miami, Florida + 10 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 200 mg/mL
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
- Conditions
- Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Enpatoran, Placebo, Standard of care (SoC)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Troy, Michigan + 1 more
- Conditions
- Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
- Interventions
- SC291
- Biological
- Lead sponsor
- Sana Biotechnology
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
- Conditions
- Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
- Interventions
- Enpatoran, Placebo, Standard of care (SoC)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Upland, California • DeBary, Florida • Pembroke Pines, Florida + 1 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 27 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- rapcabtagene autoleucel
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Bernardino, California • San Francisco, California + 10 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Sifalimumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 24
- States / cities
- Anniston, Alabama • Scottsdale, Arizona • San Leandro, California + 21 more
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Elsubrutinib, Placebo for elsubrutinib, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 47
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
- Interventions
- AZD5492
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 4 more
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Vonsetamig, Odronextamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
- Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
- Interventions
- Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
- Other
- Lead sponsor
- Arkansas Heart Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas